Other substances

Canrenone

A mineralcorticoid receptor antagonist.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
1
 Clinical trials

General information

Canrenone is an aldosterone antagonist. Its activity leads to increase in sodium excretion and inhibition of potassium excretion in the kidneys (NCIt).

Canrenone on DrugBank
Canrenone on PubChem
Canrenone on Wikipedia


 

Structure image - Canrenone

C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]45CCC(=O)O5)C

Supporting references

Link Tested on Impact factor Notes Publication date
Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region
ACE2 Preprint 		in vitro Jun/11/2020
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Severe severity Small molecule Moderate severity Cohort study 		Patients 3.30

Significant improvement in clinical status (including oxygenation, inflammation parameters, and blood pressure) and increase in event-free rate and survival rate. Sample size: 30 + 39 (RAAS inhibitors and/or vasodilatators). Dosage: 200 mg IV daily for 14 ± 11 days (at least 2 consecutive).


 Sep/11/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04977960 Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 Not yet recruiting Phase 2 Sep/01/2021 Dec/01/2022
  • Alternative id - MINECRAFT
  • Interventions - Drug: Potassium Canrenoate
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 180
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - in-hospital death|Need of invasive mechanical ventilation throughout hospitalization|Duration of hospitalization for alive patients|Drug intolerance|Number of hypotensive events|Number of hyperkaliemias events|Number of renal failures|Change in Sequential Organ Failure Assessment (SOFA) score from randomization to 7 days after randomization|Change in inflammatory status|Change in respiratory parameters|Changes in features of pulmonary interstitial disease measured by chest X-Ray|Changes in [K+]hematic, renin, AngII, Ang1-7, Ang1-9, aldosterone and structurally related steroids|Correlation between levels of [K+]hematic, renin, AngII, Ang1-7, Ang1-9, aldosterone and structurally related steroids, at basal level (randomization) and clinical outcomes (in-hospital death, need of invasive mechanical ventilation, SOFA score)
Export (.csv)